
Complizen is an AI-driven platform that simplifies FDA compliance for medical device companies by providing affordable, quick, and user-friendly guidance. The platform offers an all-in-one compliance solution including document management, real-time alerts, automated reporting, and expert US Agent services for foreign businesses. Powered by advanced AI, Complizen interprets complex FDA regulations, delivers real-time updates, and automates routine compliance tasks to save time and reduce costs. It streamlines FDA facility and product registrations, helping companies accelerate their path to market with precise regulatory insights and multilingual support. Complizen is trusted by industry leaders and aims to transform regulatory workflows with intelligent automation and comprehensive compliance management.

Complizen is an AI-driven platform that simplifies FDA compliance for medical device companies by providing affordable, quick, and user-friendly guidance. The platform offers an all-in-one compliance solution including document management, real-time alerts, automated reporting, and expert US Agent services for foreign businesses. Powered by advanced AI, Complizen interprets complex FDA regulations, delivers real-time updates, and automates routine compliance tasks to save time and reduce costs. It streamlines FDA facility and product registrations, helping companies accelerate their path to market with precise regulatory insights and multilingual support. Complizen is trusted by industry leaders and aims to transform regulatory workflows with intelligent automation and comprehensive compliance management.
What they do: AI platform that simplifies FDA regulatory and compliance workflows for medical device companies
Headquarters: Miami, Florida
Stage / funding: Private, Pre-Seed (no public funding details beyond a listed last round date)
Team size: 1-10 employees
Regulatory compliance and FDA submissions for medical devices
Regulatory technology / Healthtech
Crunchbase lists a Pre-Seed round with this date but public details on amount and investors are not provided in the available evidence.